Heating chemotherapy drugs may improve bladder cancer treatment

May 17, 2016, Taylor & Francis

Scientists have found that heating the chemotherapy drug mitomycin-C prior to using it for treating bladder cancer may radically improve its efficacy. The findings, published in the International Journal of Hyperthermia, are the result of a four-and-a-half-year study by medics based at Comarcal Hospital, Monforte, Spain.

The 'Recirculant hyperthermic IntraVEsical chemotherapy (HIVECä)' treatment devised by the researchers involved heating a solution of mitomycin-C and diluted water to a target temperature of 43 °C prior to delivery into the . The drugs were recirculated at 200 mL per minute at a stable pressure, and the temperature inside the bladder was maintained for 60 minutes.

40 took part in the study, split into two groups – one which received the HIVECä treatment prior to a resection of the bladder, and another which received HIVEC after resection of the bladder.

97% of the patients were able to complete the full course of HIVECä treatments, and the majority of participants responded well to the treatment and show low rates of recurrence. Furthermore, the majority of the side-effects were low grade and had very little effect on the treatment plan.

The majority of bladder cancers can be treated by endoscopic surgical removal or ablation of the tumour tissue. However, some patients require further treatment, which involves circulating drugs around the bladder. When this fails, few options exist but to remove the bladder – a highly morbid and invasive procedure.

Commonly Bacillus Calmette–Guérin (BCG) is used as the most effective treatment for non-muscle invasive . Mitomycin-C is typically less effective than BCG, but the authors believe that heating the solution increases the efficacy of the drug in part due to the increased solubility at higher temperature, and in part due to the increased permeability of the bladder lining.

The researchers also modelled the cost savings per patient of the HIVECä , and estimate it to be €687 after three years.

Surprisingly, they even treated some patients with HIVEC instead of the standard endoscopic surgery and found that in the majority of patients the tumors completely disappeared and did not come back within their brief follow-up of a few years. This suggests that HIVEC might be a less invasive alternative to surgery in some patients, an exciting finding which if confirmed by others, will be game changing.

Explore further: Possible new treatment for bladder cancer using a mycobacterium

More information: Alejandro Sousa et al. Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate–high-risk non-muscle-invasive bladder cancer, International Journal of Hyperthermia (2016). DOI: 10.3109/02656736.2016.1142618

Related Stories

Possible new treatment for bladder cancer using a mycobacterium

October 6, 2015
Universitat Autònoma de Barcelona researchers have found a mycobacterium that is more effective in treating superficial bladder cancer and does not cause infections, unlike those used up to now.

Narrow band imaging can reduce recurrence of bladder tumors

April 28, 2016
Research into bladder tumour surgery has found that using narrow band imaging can significantly reduce the risk of disease recurrence.

A molecular subtype of bladder cancer resembles breast cancer

March 17, 2016
Bladder cancer is the fourth most common cancer among men in the United States. While low-grade tumors have a very favorable prognosis, muscle-invasive and metastatic tumors have poorer survival rates.

Phase III research represents potential shift in standard of care for bladder cancer

April 2, 2012
Use of the Connaught strain of bacillus Calmette-Guérin, an adjuvant immunotherapy used in the treatment of non-muscle-invasive bladder cancer, significantly reduced cancer recurrence compared with the Tice strain of ...

Clinical trial could lead to new bladder cancer drug

November 24, 2015
A bladder cancer drug tested in a University of Hawai'i Cancer Center clinical trial is getting closer to Food and Drug Administration (FDA) approval. The new drug, an interleukin 15 superagonist complex (ALT-803), combined ...

Bladder cancer recurrence and mortality could decline with better treatment compliance

June 5, 2013
(Medical Xpress)—Researchers at UCLA's Jonsson Comprehensive Cancer Center led by Dr. Karim Chamie have found that more intense surveillance and treatment of bladder cancer in the first two years after diagnosis could reduce ...

Recommended for you

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

Some brain tumors may respond to immunotherapy, new study suggests

December 10, 2018
Immunotherapy has proved effective in treating a number of cancers, but brain tumors have remained stubbornly resistant. Now, a new study suggests that a slow-growing brain tumor arising in patients affected by neurofibromatosis ...

Study finds higher risk of breast cancer for women after giving birth

December 10, 2018
Younger women who have recently had a child may have a higher risk of breast cancer than their peers of the same age who do not have children, according to a large-scale analysis co-led by a University of North Carolina Lineberger ...

Researchers develop personalized medicine tool for inherited colorectal cancer syndrome

December 10, 2018
An international team of researchers led by Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has developed, calibrated, and validated a novel tool for identifying the genetic changes in Lynch syndrome genes ...

Study shows key enzyme linked to therapy resistance in deadly lung cancer

December 10, 2018
Researchers at The University of Texas MD Anderson Cancer Center have identified a link between an enzyme tied to cancer formation and therapy resistance in patients with epidermal growth factor receptor (EGFR)-mutant non-small ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.